Institut National De La Sante Et De La Recherche Medicale

Assistance Publique-Hopitaux De Paris

Universitë De Bordeaux

Université De Paris

Universite Paris Xiii Paris-Nord

Chu De Bordeaux

Gilles Wainrib

Xavier Treton

Eric Ogier-Denis

Yoram Bouhnik

Ian Morilla

David Laharie

Mathieu Uzzan

The present invention relates to methods for predicting acute severe colitis treatment response. Currently, there is no biomarker of drug response. The present invention provides the first prediction tool for responses to first- and second-line treatments in acute severe ulcerative colitis. Putative mRNA targets of dysregulated microRNAs were identified from patient biopsies. One classifier of fifteen colonic microRNAs plus five biological values at admission were identified with a prediction accuracy of 96.6% for discriminating responders from non-responders to steroids. Using a similar method, 6 and 4 mucosal microRNA-based algorithms were identified to classify responders from non-responders to infliximab and cyclosporine. In particular, the present invention relates to methods for predicting acute severe colitis treatment response by measuring the expression levels of several miRNAs selected from the group consisting of hp_hsa-mir-3934, hp_hsa-mir-100, hsa-miR-718, hp_hsa-mir-193b, hsa-miR-3150a-5p, hp_hsa-mir-1260b, hsa-miR-938, hsa-miR-518b and hsa-miR-1468.

Methods for predicting acute severe colitis treatment response

Growing community of inventors

Paris, France

Gilles Wainrib